On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

InstitutionResearch output, impact & collaborations

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori is a institution indexed in ScholarIQ from OpenAlex.

What is known about Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori?

ScholarIQrecord summary

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori is a research organisation in Meldola, IT. OpenAlex records 6,254 works and 494,773 citations for it. 984 researchers list it as their most recent affiliation.

How many works does Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori have?

ScholarIQindexed works

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori has 6,254 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori →

How many citations does Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori have?

ScholarIQcitation count

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori has 494,773 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori →

How many researchers are at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori?

ScholarIQresearcher count

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori has 984 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori?

ScholarIQavg h-index

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori has an average h-index of 70.5 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori?

ScholarIQror

The ROR for Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori is on the source record.

Open the ROR →

What is the OpenAlex record for Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori?

ScholarIQopenalex

The OpenAlex for Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori?

ScholarIQtop researchers by citations

Giovanni Martinelli · Chronic Myeloid Leukemia Treatments

2,324 works60,743 citations

Lucio Crinò · Lung Cancer Treatments and Mutations

579 works45,099 citations

Giovanni Paganelli · Radiopharmaceutical Chemistry and Applications

552 works26,237 citations

Massimiliano Bonafè · Genetics, Aging, and Longevity in Model Organisms

272 works22,323 citations

Gianantonio Rosti · Chronic Myeloid Leukemia Treatments

517 works16,946 citations

What are the most-cited papers on Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori?

ScholarIQmost cited works

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer

New England Journal of Medicine. 20159,504 CitationsOPEN ACCESS

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel

New England Journal of Medicine. 20158,599 CitationsOPEN ACCESS

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne

New England Journal of Medicine. 20133,411 CitationsOPEN ACCESS

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel, Yuh-Min Chen, Keunchil Park, Sang-We Kim, Caicun Zhou, Wu‐Chou Su, Mengzhao Wang, Yan Sun, Dae Seog Heo, Lucio Crinò, Eng-Huat Tan, Tsu-Yi Chao, Mehdi Shahidi, Xiuyu Julie Cong, Robert M. Lorence, James Chih‐Hsin Yang

The Lancet Oncology. 2012957 Citations

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz‐Ares, Adam Płużański, Karen L. Reckamp, Marco Angelo Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlési, Scott Antonia, Óscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer A. Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood‐Chirchir, Diane Healey, Julie R. Brahmer, Wilfried Eberhardt

Journal of Clinical Oncology. 2017877 CitationsOPEN ACCESS

How much of the research on Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori is open access?

ScholarIQopen access share

67%OPEN ACCESS

Gold

Green

25%

Hybrid

Bronze

33%

Closed

33%